# A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121

> **NCT06025773** · PHASE1 · COMPLETED · sponsor: **Addpharma Inc.** · enrollment: 24 (actual)

## Conditions studied

- Gastro Esophageal Reflux

## Interventions

- **DRUG:** Lansoprazole 15 mg
- **DRUG:** Lansoprazole 15mg/Calcium carbonate 600mg

## Key facts

- **NCT ID:** NCT06025773
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-15
- **Primary completion:** 2024-04-19
- **Final completion:** 2024-04-19
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06025773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06025773, "A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06025773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*